Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19

• Status: Terminated
• Trial end date: 2020-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Coronaviruses (CoV) are positive-sense single-stranded RNA viruses that infect a wide range of hosts producing diseases ranging from the common cold to serious / fatal events. Nitazoxanide (NTZx) is a derivative of 5-nitrothiazole, synthesized in 1974 by Rosignol - Cavier. NTZx has powerful antiviral effects through the phosphorylation of protein kinase activated by double-stranded RNA, which leads to an increase in phosphorylated factor 2-alpha, an intracellular protein with antiviral effects. The purpose of this study is to contrast the beneficial effect of NTZx vs NTZx plus hydroxychloroquine in patients Coronavirus Disease (COVID-19) as well as against other treatments.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hugo Mendieta Zeron
• Treatments: Hydroxychloroquine; Nitazoxanide

Criteria

Inclusion Criteria:

• COVID-19 positive patients

• Treated at the Health Institute of the State of Mexico (ISEM).

• With risk factors to get complicated: age more than 60 years old, diabetes mellitus or obesity grade II or more.

Exclusion Criteria:

• Patients who have inherent contraindications to each drug.